3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
Head & Neck
1
Genitourinary
1
Endocrine
1
CNS
1
Conditions
Brain Neoplasms
4
Glioma
3
Thyroid Cancer, Papillary
2
Sarcoma
2
Salivary Gland Neoplasms
2
Neoplasm Metastasis
2
Melanoma
2
Central Nervous System Neoplasms
2
Wilms Tumor
1
Sarcoma, Ewing
1
Recurrence
1
Pancreatic Neoplasms
1
Ovarian Neoplasms
1
Neuroendocrine Tumors
1
Neuroblastoma
1
Nephroma, Mesoblastic
1
Neoplasms by Site
1
Neoplasms by Histologic Type
1
Neoplasms
1
Medulloblastoma
1
Lymphoproliferative Disorders
1
Lymphoma, Large-Cell, Anaplastic
1
Hematologic Neoplasms
1
Head and Neck Neoplasms
1
Colorectal Neoplasms
1
Cholangiocarcinoma
1
Carcinoma, Renal Cell
1
Carcinoma, Non-Small-Cell Lung
1
Breast Neoplasms
1
Interventions
Filgrastim
9
X-Rays
7
Phantoms, Imaging
7
Specimen Handling
6
Magnetic Resonance Spectroscopy
6
Granulocyte Colony-Stimulating Factor
6
Temozolomide
5
Nuclear Medicine Department, Hospital
5
Melphalan
5
Cyclophosphamide
5
Busulfan
5
Stem Cell Transplantation
4
Carboplatin
4
Biopsy
4
Topotecan
3
Thiotepa
3
Radiotherapy
3
Peripheral Blood Stem Cell Transplantation
3
Itraconazole
3
Ifosfamide
3
ulixertinib
2
tipifarnib
2
tazemetostat
2
selpercatinib
2
sargramostim
2
palbociclib
2
olaparib
2
liposomal amphotericin B
2
larotrectinib
2
ixabepilone
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Wilms Tumor
×
entrectinib
×
CNS
×
Clear all
NCT02650401
2026-03-25
STARTRK-NG
Hoffmann-La Roche
Phase 1/2
Active not recruiting
69 enrolled
1 FDA